Original Articles

Characterization of Bacteriophage vB_PaeS_TUMS_P6 Infecting Pseudomonas aeruginosa

Abstract

Background:   Pseudomonas aeruginosa is an important pathogen in healthcare settings that poses significant challenges due to its ability to rapidly develop antibiotic resistance. Its propensity to form biofilms and adapt to host defenses makes it even more difficult to treat, leading to prolonged and debilitating illnesses. So, it is vital to prioritize efforts to develop new strategies for treating infections caused by this pathogen. In the present work, morphological and biological characteristics of vB_PaeS_TUMS_P6 (P6), a lytic phage against P. aeruginosa, belonging to the genus Luzseptimavirus were fully described.

Methods:   P. aeruginosa ATCC 27853 was used for propagation and biological characterization of P6. Its morphology was assessed using transmission electron microscopy (TEM). Adsorption rate assay, one-step growth curve analysis and time-kill experiment were analyzed. Host Range of P6, as well as pH and thermal stability were also determined.

Results:   The results showed that it was of classic podovirus morphology and had a short latent period. It could kill bacteria at multiplicity of infection as low as 0.01 and also infect some multidrug-resistant clinical isolates. Stability data suggested that P6 remained stable in various temperatures and pH levels, which is a beneficial characteristic for phage therapy in different situations.

Conclusion:   This study presents promising data supporting the future use of P6 as a candidate for phage therapy.

1. Jurado-Martín I., Sainz-Mejías M.McClean S. Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci 2021;22(6).
2. Kunz Coyne AJ, El Ghali A, Holger D, et al. Therapeutic strategies for emerging multidrug-resistant Pseudomonas aeruginosa. Infect Dis Ther 2022; 11(2):661-82.
3. WHO. One health. World Health Organization 2017;736.
4. Fong SA, Drilling AJ, Ooi ML, et al. Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis. Transl Res 2019; 206:41-56.
5. Van Nieuwenhuyse B, Van der Linden D, Chatzis O, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nature commun 2022; 13(1):5725.
6. Ferry T, Kolenda C, Laurent F, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nature commun 2022; 13(1):4239.
7. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011; 1(2):111-4.
8. Fernández L, Gutiérrez D, García P, et al. The perfect bacteriophage for therapeutic applications-a quick guide. Antibiotics (Basel) 2019; 8(3).
9. Spilker T, Coenye T, Vandamme P, et al. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol 2004; 42(5):2074-9.
10. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18(3):268-81.
11. Letarov AV, Kulikov EE. Determination of the Bacteriophage Host Range: culture-based approach. Methods Mol Biol 2018; 1693:75-84.
12. Ackermann HW. Basic phage electron microscopy, in bacteriophages: methods and protocols, Volume 1: isolation, characterization, and interactions, MRJ. Clokie and AM. Kropinski, Editors. 2009, Humana Press: Totowa, NJ. p. 113-126.
13. Kropinski AM. Measurement of the rate of attachment of bacteriophage to cells. Methods Mol Biol 2009; 501:151-5.
14. Kropinski AM., Practical advice on the one-step growth curve, in Bacteriophages. 2018, Springer. p. 41-47.
15. Shahrbabak SS, Khodabandehlou Z, Shahverdi AR., et al. Isolation, characterization and complete genome sequence of PhaxI: a phage of Escherichia coli O157 : H7. Microbiology (Reading) 2013; 159(Pt 8): 1629-38.
16. Jurczak-Kurek A., Gąsior T, Nejman-Faleńczyk B, et al. Biodiversity of bacteriophages: morphological and biological properties of a large group of phages isolated from urban sewage. Scientific Reports 2016; 6(1):34338.
17. Onsea J, Uyttebroek S, Chen B, et al. Bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force (the phageforce study protocol). Viruses 2021; 13(8).
18. Klai N, Sellamuthu B, Bacteriophages isolated from hospital wastewater and its role in controlling drug-resistant pathogens, in current developments in biotechnology and bioengineering, RD. Tyagi, et al., Editors. 2020, Elsevier. p. 327-76.
19. Dennehy JJ, Abedon ST, Phage infection and lysis, in Bacteriophages: biology, technology, therapy, DR. Harper, et al., Editors. 2021, Springer International Publishing: Cham p. 341-83.
20. Bull JJ, Gill JJ. The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front Microbiol 2014; 5:618.
21. Roach DR, Leung CY, Henry M, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 2017; 22(1):38-47.
Files
IssueVol 12 No 1 (2024) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/jmb.v12i1.15021
Keywords
Antimicrobial Resistance Bacteriophage Pseudomonas aeruginosa.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Kamyab H, Torkashvand N, Shahverdi AR, Khoshayand MR, Sharifzadeh M, Sepehrizadeh Z. Characterization of Bacteriophage vB_PaeS_TUMS_P6 Infecting Pseudomonas aeruginosa. J Med Bacteriol. 2024;12(1):59-68.